Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer by Lin, Lin et al.

































































View OnlineDirect infusion mass spectrometry or liquid chromatography mass
spectrometry for human metabonomics? A serum metabonomic study of
kidney cancer
Lin Lin,a Quan Yu,a Xiaomei Yan,a Wei Hang,*a Jiaxin Zheng,b Jinchun Xing*b and Benli Huanga
Received 26th April 2010, Accepted 5th August 2010
DOI: 10.1039/c0an00265hSerum samples from kidney cancer patients and healthy controls were analyzed by both direct infusion
mass spectrometry (DIMS) and liquid chromatography-mass spectrometry (LC-MS) with a high
resolution ESI-Q-TOFMS. The classification and biomarker discovery capacities of the two methods
were compared, and MS/MS experiments were carried out to identify potential biomarkers. DIMS had
comparable classification and prediction capabilities to LC-MS but consumed only5% of the analysis
time. With regard to biomarker discovery, twenty-three variables were found as potential biomarkers
by DIMS, and 48 variables were obtained by LC-MS. DIMS is recommended to be a fast diagnostic
method for kidney cancer, while LC-MS is necessary when comprehensive screening of biomarkers is
required.Introduction
Metabonomics has been defined by Nicholson as the quantitative
measurement of the dynamic multiparametric response of
a living system to pathophysiological stimuli or genetic modifi-
cation.1 It concerns low molecular weight compounds in biofluids
and other complex matrixes, which are known as metabolites.2,3
Many analytical techniques have been developed for metabo-
nomic studies, including nuclear magnetic resonance spectroscopy
(NMR), mass spectrometry (MS), fourier transform infrared
spectroscopy (FT-IR), and Raman spectroscopy.4–7 With the
advantages of high sensitivity, high accuracy, wide dynamic range,
robustness to molecular weight (MW) determination, and the
ability to identify metabolites, mass spectrometry has become the
workhorse of metabonomics research in recent years.8–11
There is a trade-off between comprehensive sample analysis
and high sample throughput in MS-based metabonomics.
Currently, liquid chromatography coupled to MS (LC-MS) is
a reference tool for metabonomics analysis.12,13 Although being
beneficial to comprehensive analysis, the chromatographic step
limits the throughput, especially when the number of sample sets
is large.14 Furthermore, the pretreatment of LC-MS data (peak
alignment and retention time correction) before chemometrics
analysis is problematic because of the possible loss of some
relevant analytical signals or the generation of artifacts by erratic
retention time shift correction or background subtraction.15 On
the contrary, direct infusion mass spectrometry (DIMS), by
avoiding any prior chromatographic steps, has the greatest
potential for high throughput and provides more concise raw
data than LC-MS. DIMS has been used in targeted metabolite
analysis and global metabolite profiling in the last decade.8,16 AaDepartment of Chemistry, Key Laboratory of Analytical Sciences, College
of Chemistry and Chemical Engineering, Xiamen University, Xiamen,
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2970 | Analyst, 2010, 135, 2970–2978method using DIMS for the analysis of 23 amino acids in dry
blood spots without chemical derivatization has been devel-
oped.17 The quantitative analyses of metabolites by DIMS have
been validated and were used in large newborn-screening
programs to detect and diagnose inherited metabolic disorders in
the neonatal period.18,19 In general, DIMS applications for
metabolite profiling are mainly concentrated in the microbial and
plant arenas.16,20 DIMS has been used for the global analysis of
intracellular metabolites in different strains of the yeast S. cer-
evisiae.21 A nontargeted metabolic analysis has been performed
on strawberry fruit and tobacco flower extracts with direct
infusion Fourier transform ion cyclotron resonance mass spec-
trometry (FTICR-MS).22 Viant et al.23 reported an optimized
strategy for wide-scan direct infusion nanoelectrospray FTICR-
MS. This method collected multiple adjacent selected ion
monitoring (SIM) windows that were stitched together using
novel algorithms. Using the SIM-stitching approach, an increase
in the dynamic range and mass accuracy was achieved for
metabonomic studies. Although DIMS has been explored in
metabonomic analysis with low mass resolution analyzers,
including quadrupole and ion-trap,21,24,25 high mass resolution
devices such as time of flight (TOF) mass spectrometers and
FTICR-MS are more suited for such an approach, especially for
global metabonomics analysis.23,26–28 Mass spectrometry with
high resolving power unambiguously discriminates isobaric ions;
elemental compositions of low molecular mass analytes can be
obtained by accurate mass measurements with ppm errors in
mass spectra. Regardless of what devices used in DIMS, matrix
effects are inevitable because the samples are infused together
without separation, which may result in reduced sensitivity and
deteriorated capability for metabolite identification.29,30 Another
limitation of DIMS is its inability to discriminate between
isomeric compounds based solely on accurate mass.31 Thus,
a practical comparison of DIMS and LC-MS would be both
interesting and useful. However, few studies have compared the
two methods in real metabonomic analysis, especially using the

































































View OnlineIn this study, serum samples from kidney cancer patients and
healthy controls were used as models to check the performance of
LC-MS and DIMS with a high resolution ESI-Q-TOFMS. The
resulting data were analyzed by multivariate data analysis.
MS/MS experiments were carried out to identify potential
biomarkers. The classification and biomarker discovery capac-
ities of the two methods were compared.Experimental
Reagents and materials
HPLC-grade methanol and acetonitrile were purchased from
Merck (Darmstadt, Germany). Formic acid was obtained from
Fluka (Switzerland). Distilled water (18.2 MU) was prepared
using a Milli-Q water purification system (Millipore, MA, USA).
All standards were purchased from Sigma-Aldrich (MO, USA).Sample collection and storage
Thirty-one kidney cancer patients and 20 healthy volunteers
from First Hospital of Xiamen were enrolled in this study. All of
the patients were diagnosed using a histopathology examination
and none had received chemotherapy, radiation or undergone
nephrectomy before sample collection. The detailed demo-
graphic profiles of the participants are provided in Table 1. The T
test was carried out to check whether the age and body mass
index (BMI) distributions differed significantly between the two
classes. The statistical test showed that the two classes were well
matched. All of the blood samples were collected before break-
fast with consent and then centrifuged at 3,000  g for 10 min at
4 C. The sera were stored at 80 C prior to any further sample
preparation or analysis. An in-house quality control (QC)
sample was prepared by pooling and mixing the same volume of
each sample.32Sample preparation
The sera were thawed at room temperature before analysis. A
volume of 600 mL of methanol was added to 200 mL of sera. After
vortexing, the mixture was set aside at room temperature for 10
min and then centrifuged at 12,000  g for 10 min at 4 C. The
supernatant was filtered through a 0.2-mm regenerated cellulose
filter (Agilent Technologies, Inc., Boeblingen, Germany) before
LC-MS analysis. For DIMS analysis, the filtered supernatant
was further diluted 5-fold with 0.1% formic acid. To choose the
most appropriate dilution, the same samples with different
dilutions (2-fold, 5-fold, 10-fold, and 20-fold) were infused intoTable 1 Demographic and clinical data
Kidney cancer
patients Healthy controls p valvea
Number 31 20 —
Age (median, range) 56, 40–72 52, 43–71 0.15
Male/female ratio 19/12 12/8 —
BMI (median, range) 22.1, 16.4–27.6 23.4, 18.1–27.4 0.19
Race Chinese Chinese —
a p values were calculated from student T-test.
This journal is ª The Royal Society of Chemistry 2010the mass spectrometer for a pilot study. Five-fold dilution was
ultimately selected because the maximum number of peaks (S/N
> 5) were detected with this dilution, indicating the best overall
response (low ion suppression and high sensitivity).Mass spectrometer
A high resolution electrospray mass spectrometer (MicrOTOF-Q
II, Bruker Daltonics Corporation, USA) was operated in positive
ion mode for both LC-MS and DIMS analysis. This mass
spectrometer can provide accurate mass measurements with
errors of less than 5 ppm using external calibration and mass
resolving power of 20,000. The positive ion mode was used
because more compounds can be ionized in this mode and
because it is more widely used in serum metabolite profiling.33,34
The capillary voltage was set at 4500 V with an end plate offset
potential of 500 V. Data were collected from 50 to 1000 m/z
with an acquisition rate of 1 spectrum per second. Because the
sample flow rate differed between the two methods, the nebulizer
gas and dry gas parameters were individually optimized. For LC-
MS analysis, the dry gas was set to 6 L min1 at 220 C with
a nebulization gas pressure of 0.7 bar, while for DIMS, the dry
gas was set to 1.2 L min1 at 120 C with a nebulization gas
pressure of 0.4 bar. In the MS/MS experiments, argon was used
as the collision gas and the collision energy was adjustable from
10 eV to 30 eV.LC-MS analysis
LC separation was performed on a 2.1  150-mm Acclaim C18
3-mm column (Dionex, USA) using a high performance liquid
chromatography system (Ultimate-3000, Dionex, USA). The
column was maintained at 30 C and the mobile phase was 0.1%
formic acid (A) and acetonitrile with 0.1% formic acid (B). The
gradient started with 15% (B) for 2 min, and increased to 40% (B)
over 7 min, and then 98% (B) over 7–30 min. After holding at
98% (B) for 5 min, the composition was returned to its initial
conditions and maintained for three different column volumes
for equilibration. The sample injection volume was 15 mL. The
chromatograph was coupled directly to the mass spectrometer at
a flow rate of 200 mL min1 without splitting. A QC sample and
a blank were analyzed after every 5 samples to identify the
sample carryover and check for stability.DIMS analysis
A syringe pump (Razel, Connecticut, USA) was used at a flow
rate of 3 mL min1 to infuse samples directly into the mass
spectrometer. The infusion time was 30 s for each sample.
Including the manual operation time, the whole analysis time
was about 2 min for each sample. A longer infusion time was not
used because the signal was sufficiently stable within 30 s. Longer
infusion time does not significantly improve the S/N or the
number of detected features. To avoid the cross-contamination,
a blank run was inserted between sample runs. A QC sample was


































































The raw data acquired from LC-MS were pretreated by the
DataAnalysis 4.0 software (Bruker Daltonics Corporation) to
find compounds with molecular features. Next, the data were
exported into the ProfileAnalysis 1.1 software (Bruker), which
allowed peak alignment, background noise subtraction and data
reduction, yielding a table of mass and retention time pairs with
associated intensities for all detected peaks. The main parameters
were set as follows: retention time range 1–40 min, mass range
50–1000, mass window 0.5, retention time window 1 min, and
noise elimination level 5. Variables that did not exist in 80% of
participants in one group were filtered out. For DIMS, the data
pretreatment is much easier because there is no need to take
account of retention time. ProfileAnalysis 1.1 software was also
used to convert the mass spectra into a variable table that dis-
played mass and associated intensities as columns for all samples.
The DIMS main parameters were set as follows: mass range 50–
1000, mass window 0.5, and noise elimination level 5. Variables
were also filtered as mentioned above.Chemometrics analysis
The data were exported to the SIMCA-P 11.5 demo version
(Umetrics AB, Umea, Sweden) for multivariate data analysis.
Both principle component analysis (PCA) and partial least
squares-discriminant analysis (PLS-DA) were used for modeling
the differences between the kidney cancer patients and the
healthy controls. PCA is an unsupervised data analysis technique
that reduces original data to a few principal components while
retaining the features that contribute most to the variance. PLS-
DA, in contrast, is a supervised extension of PCA that uses class
information to maximize the separation among classes ofFig. 1 Typical LC-MS base peak chromatograms (BPC) obtained from s
2972 | Analyst, 2010, 135, 2970–2978observations. Pareto (Par) scaling was used in all models to avoid
chemical noise.Results and discussion
Metabonomic profile of LC-MS and DIMS
Typical LC-MS base peak chromatograms (BPC) of serum
samples from a cancer patient and a healthy control are shown in
Fig. 1. Several base peaks are marked on the chromatogram to
provide an intuitive display. Fig. 2 presents the typical metabolic
fingerprints of the same samples by DIMS analysis. About 2000
peaks were detected in the mass spectrum, with intensities
ranging from 2  102 to 1  106 (arbitrary units) and S/N larger
than 5. Obvious differences can be observed between the
fingerprints of a cancer patient and a healthy control using
DIMS analysis.
To give an overview of the differences between LC-MS and
DIMS in serum metabonomic profiles, a summed mass spectrum
from the LC-MS analysis is presented in Fig. 3(a). The ion of m/z
149.01 was a major solvent peak in LC-MS analysis. Comparing
the main peaks in the mass spectra, most of the ions in the DIMS
mass spectrum have a m/z difference of 21.98 compared to those
of LC-MS, corresponding to the mass of [Na–H]. Thus, the
compounds were apt to form sodium ion adducts in the DIMS
analysis. It is worth mentioning that because the summed mass
spectrum of the LC-MS is the summation of all the ions during
the entire analysis time, the signal of low abundance ions can be
overlaid by the summed background. Therefore, direct
comparison of the number of ions between the spectra is not
meaningful.
The stability of the analytical system is one of the most
important factors in obtaining valid data for metabonomicerum samples of (a) a healthy control and (b) a kidney cancer patient.
This journal is ª The Royal Society of Chemistry 2010
Fig. 2 Typical metabolic fingerprints obtained from serum samples of (a) a healthy control and (b) a kidney cancer patient.

































































View Onlineanalysis. A QC sample was injected every 5 samples to monitor
and evaluate the stability of the two methods. In order to eval-
uate the method stability and repeatability roundly, quality
assurance of all detected peaks across the QC samples was per-
formed.35 The variations in retention times of all the peaks for
LC-MS were less than 0.2 min, and the variations of m/z valuesThis journal is ª The Royal Society of Chemistry 2010for both methods were less than 10 mDa. The relative standard
deviations (RSDs) of the peak areas (for LC-MS) and peak
intensities (for DIMS) were calculated across the QC samples. In
LC-MS analysis, 68% (using peak area) of all the peaks have
RSDs less than 15%; and 82% and 90% of the peaks have RSDs
less than 20 and 30%, respectively. For DIMS, the number ofAnalyst, 2010, 135, 2970–2978 | 2973



































































View Onlinepeaks showing repeatability at RSDs of 15, 20 and 30% was 79%,
87% and 93%, respectively. These results demonstrate the
excellent stability and reproducibility of both methods.R2Y(cum) Q2(cum) Var No.a Marker No.b
LC-MS 0.986 0.928 8360 48
DIMS 0.969 0.931 1801 23
a Imported Var No.: number of the variables imported to build the
model. b Discovered Marker No.: number of variables discovered as
potential markers.Comparison of classification and prediction abilities
The datasets from LC-MS and DIMS, containing 8360 and 1801
variables respectively, were imported to SIMCA-P for multi-
variate statistical analysis. PCA was used as an unbiased statis-
tical method to detect any inherent trends within the data and to
identify any potential outliers that could affect subsequent
discriminant analysis. As shown in Fig. 4, obvious separation
trends can be observed between the two groups by both methods,
indicating inherent metabolic changes of the kidney cancer
patients compared to the controls. According to the R2X (cum)
parameter in PCA, 40.1% and 55.3% of the variables can be
explained by the first two components of the models built on LC-
MS and DIMS datasets, respectively.
To further study the differences between the kidney cancer
patients and the healthy controls, and to find out potential
biomarkers, supervised PLS-DA was subsequently used. 80% of
the data were randomly extracted from each group to create
a training set for building the PLS model. The remaining data
formed the independent prediction set and were used to evaluate
the developed model. The classification and prediction results are
shown in Fig. 5. Distinct clustering between the patients and
controls was achieved with both methods. All of the samples in
the prediction set were classified to the area in which they were
supposed to be. In PLS-DA, R2Y (cum) and Q2 (cum) parameters
were used for the evaluation of the models, indicating fitness and
prediction ability, respectively.36,37 The R2Y (cum) and Q2 (cum)
values obtained by DIMS are 0.969 and 0.931, respectively,Fig. 4 PCA scores plots based on the (a) LC-MS dataset and
Fig. 5 PLS-DA scores plots for response variables (C patient training set, -
set): (a) LC-MS training set with prediction set overlaid and (b) DIMS train
2974 | Analyst, 2010, 135, 2970–2978which are comparable to the values of 0.986 and 0.928 achieved
by LC-MS (summarized in Table 2). It should be noticed that
although fewer variables were obtained, DIMS analysis gener-
ated as robust a model as LC-MS. Considering that the analysis
time for each sample in DIMS is only 2 min, compared with
several tens of minutes for LC-MS, DIMS undoubtedly provides
a much higher sample throughput. DIMS could be developed as
a fast prognostic or diagnostic method for kidney cancer.Comparison of biomarker discovery abilities
To discover the potential biomarkers among thousands of vari-
ables, parameter VIP (Variable Importance in the Projection)
was employed to reflect variable importance. A variable is
considered important for the model when its VIP is above 1.0.38,39
To focus on highly significant variables, only those with VIP
above 2.0 were considered here. The T-test was performed in
succession, and the variables without significant differences
between the patients and the controls (p > 0.01) were eliminated.(b) DIMS dataset (C kidney cancer patients, -controls).
control training set, : patient prediction set, and A control prediction
ing set with prediction set overlaid.
This journal is ª The Royal Society of Chemistry 2010
Table 3 Potential biomarkers identified from LC-MS and DIMS analysis
LC-MS DIMS
Identified resultsNo. m/z Adduct Fold changea p valueb No. m/z Adduct Fold changea p valueb
1 524.38 M + H [1+] 2.18 7.12E-11 1 546.35 M + Na [1+] 4.09 2.21E-21 LPCc (18 : 0)e
2 991.71 2M-H [1+] 2.70 2.68E-17 LPC (16 : 0)e
3 496.35 M + H [1+] 1.65 2.47E-14 2 518.32 M + Na [1+] 3.36 3.09E-21 LPC (16 : 0)e
4 522.36 M + H [1+] 1.47 3.02E-08 3 544.34 M + Na [1+] 2.19 1.17E-12 LPC (18 : 1)e
5 520.34 M + H [1+] 1.42 1.01E-03 4 542.32 M + Na [1+] 2.10 1.92E-10 LPC (18 : 2(9Z,12Z))f
6 310.31 M + H [1+] 8.61 9.56E-16 5 332.29 M + Na [1+] 3.21 1.12E-20 UNg
7 274.27 M + H [1+] +6.34 5.80E-12 6 274.27 M + H [1+] +3.08 8.73E-07 C16 sphinganinef
8 482.36 M + H [1+] 3.53 1.81E-17 LPC (15 : 0)f
9 510.36 M + H [1+] 3.14 2.27E-17 LPC (17 : 0)e
10 508.38 M + H [1+] 3.62 7.56E-17 LPC (P-18 : 0))f
11 480.35 M + H [1+] 2.83 5.25E-13 LPC (P-16 : 0)f
12 466.33 [1+] 6.05 7.94E-18 UNg
13 184.07 [1+] 1.85 2.31E-09 7 184.07 [1+] 1.25 1.21E-05 Fragment of LPCe
14 338.34 M+ ACN +H[1+] 3.52 1.94E-07 8 360.32 M+ ACN +Na[1+] 6.23 5.70E-21 Thromboxanef
15 774.59 [1+] 8.35 3.30E-14 9 796.55 M + Na [1+] 2.04 1.49E-07 UNh
16 387.17 2M + H[1+] +11.38 7.40E-09 10 409.16 2M + Na [1+] +4.85 7.83E-06 Phenylacetylglycine e
17 468.31 M + H [1+] 2.21 1.09E-07 LPC (14 : 0)e
18 548.37 M + H [1+] 2.24 2.31E-12 11 548.37 M + H [1+] 2.22 8.05E-13 LPC (20 : 2(11Z,14Z))f
19 293.27 [1+] 8.68 1.04E-21 UNh
20 510.39 M + H [1+] 3.47 2.06E-15 LPC (O-18 : 0)f
21 464.31 [1+] 5.04 3.04E-15 UNg
22 550.39 M + H [1+] 2.23 1.77E-08 12 550.39 M + H [1+] 2.12 9.08E-09 LPC (20 : 1(11Z))f
23 438.30 [1+] 3.54 2.97E-18 UNg
24 376.32 [1+] 6.65 8.25E-19 UNg
25 105.06 [1+] +8.85 1.45E-09 UNh
26 506.36 [1+] 3.38 4.83E-13 UNg
27 317.25 [1+] 2.13 4.74E-18 UNh
28 404.21 [1+] +9.88 1.75E-04 UNh
29 280.09 [1+] 3.36 2.91E-23 13 280.09 [1+] 3.06 6.73E-25 UNh
30 838.58 [1+] 7.64 1.82E-21 14 860.58 M + Na[1+] 1.06 9.00E-17 UNg
31 822.58 [1+] 4.53 9.13E-16 15 844.55 M + Na[1+] 3.20 8.21E-18 UNg
32 538.39 M + H [1+] 2.98 2.11E-15 LPEd (22 : 0/0 : 0)f
33 293.24 [1+] 5.72 1.11E-26 UNh
34 319.29 M + Na[1+] 3.20 1.03E-16 16 319.29 M + Na[1+] 2.73 7.73E-25 Thromboxanef
35 219.02 [1+] 1.36 9.65E-07 17 219.02 [1+] 1.36 9.80E-03 UNh
36 558.32 M + H [1+] 3.41 4.30E-15 LPE (22 : 1/0 : 0)f
37 205.09 M + H [1+] 1.58 2.34E-06 L-Tryptophane
38 357.24 M + Na[1+] 3.21 1.44E-20 Tetrahydrodeoxy-corticosteronee
39 373.23 [1+] 3.58 3.01E-22 UNh
40 640.44 M + 2H[2+] +13.88 4.33E-04 Ganglioside GM3 (d18:1/25 : 0)f
41 291.26 [1+] 3.16 4.68E-17 UNh
42 397.23 [1+] 3.56 3.07E-19 UNg
43 618.42 M + 2H[2+] +9.24 5.05E-04 18 640.41 M + H + Na[2+] +3.03 1.39E-05 Ganglioside GM3 (d18:1/22 : 1)f
44 327.23 [1+] 3.53 1.10E-19 UNg
45 182.07 M + H [1+] 1.69 4.53E-15 L-Tyrosinee
46 333.24 [1+] 2.19 5.73E-25 UNh
47 104.09 [1+] 1.54 7.46E-14 19 104.09 [1+] 2.27 5.31E-23 Fragment of LPCe
48 488.32 [1+] 2.94 5.74E-19
20 381.30 [1+] 4.02 1.30E-14 UNh
21 576.28 [1+] 2.58 2.53E-20 UNh
22 361.33 [1+] 2.34 1.08E-19 UNh
23 754.55 [1+] +1.53 8.20E-03 UNh
a Fold change was calculated from the arithmetic mean values of each group. Fold change with a positive value indicates a relatively higher
concentration present in kidney cancer patients while a negative value means a relatively lower concentration compared to the healthy controls. b p
values were calculated from student T-test. c LPC: Lysophosphatidylcholine. d LPE: Lysophosphatidylethanolamine. e Metabolites formally
identified by standard samples. f Metabolites putatively annotated. g Unknown: Compounds which MS/MS spectra were not interpretable or not

































































View OnlineAs a result, 23 variables were found as potential markers by
DIMS, while 48 variables were obtained by LC-MS (Table 3).
The method of identifying compounds is as follows. First, the
quasi-molecular ion of the corresponding variable was found in
the mass spectrum. Second, the exact mass of the quasi-This journal is ª The Royal Society of Chemistry 2010molecular ion was searched on the HMDB or METLIN website
to find possible compounds within a certain mass range. Because
the variation of the measured m/z value in our experiment was
below 10 mDa, the accurate mass cutoff was set as 10 mDa.

































































View Onlinestructure information obtained from the MS/MS data, and the
standard MS/MS spectra of possible compounds were searched
on the website. Finally, the result was confirmed with commercial
standard compounds if available. Taking the variable of m/z 524
as an example, the MS/MS results from LC-MS and DIMS were
shown in Fig. 6. For LC-MS, the corresponding quasi-molecular
ion peak was found according to the retention time in the
extracted ion chromatogram of m/z 524. For DIMS, the sum
intensity of the variable m/z 524 and its sodium adduct m/z 546
was approximately one order of magnitude lower than that of
LC-MS, and the intensity of m/z 524 was only 20% of the sum
intensity. Nevertheless, the m/z 524 ion was still chosen for the
MS/MS experiment in DIMS analysis because it can be conve-
niently compared with the MS/MS spectrum of the commercial
standard or the spectra from the literature. All of the identifi-
cation results are shown in Table 3. Unfortunately, about 40% of
the potential biomarkers were unidentifiable due to insufficient
intensity for MS/MS experiments or the restrictions of metabo-
lite databases.
As shown in Table 3, most biomarkers found by DIMS were
also obtained by LC-MS. Instead of forming [M + H]+ ions in
LC-MS, the compounds prefer to form [M + Na]+ adducts in
DIMS. The complicated serum matrix not only affects the ion
adduct forms, but also reduces the biomarker detection ability.
When thousands of metabolites are infused together into the
mass spectrometer, ion suppression effects cause some
biomarkers of low abundance, low volatility, or low ionizationFig. 6 Identification of a selected marker (m/z 524): (a) MS/MS spectrum i
spectrum of the commercial standard Lysophosphatidylcholine C18:0. The c
2976 | Analyst, 2010, 135, 2970–2978efficiencies to be undetectable in the DIMS analysis. Thus, the
LC-MS method is a better choice for comprehensive screening of
potential biomarkers. On the other hand, although the DIMS
method is less information-rich, it requires only 5% of the
analysis time of the LC-MS approach and still provides roughly
half as much biomarker information, allowing quality statistical
data generation.
It is worthy to mention that more compounds can be detected
and less analysis time is needed if ultra performance liquid
chromatography (UPLC) is used instead of conventional LC.40
However, the general throughput of UPLC is not comparable to
that of DIMS. Very fast gradient elution may be used in UPLC
to obtain a throughput closer to that of DIMS, but it would
sacrifice both separation performance and detection capability.The biological changes of the potential biomarkers
The alteration of potential biomarkers in kidney cancer patients
compared to healthy controls is also presented in Table 3. A fold
change with a positive value indicates a relatively higher
concentration in kidney cancer patients, while a negative value
indicates a relatively lower concentration compared to the
healthy controls. The alteration trends (up- or down-regulation)
of corresponding biomarkers obtained by the two methods were
consistent with one another although the fold values were not
equal. The differences in the concentration ratios between the
two methods may have been due to the different datan LC-MS analysis; (b) MS/MS spectrum in DIMS analysis; (c) MS/MS
ollision energy was 20 eV.
This journal is ª The Royal Society of Chemistry 2010
Fig. 7 Variation of serum (a) LPC (16 : 0), (b) LPC (18 : 0), (c) phenylacetylglycine and (d) Ganglioside GM3 levels in kidney cancer patients compared
to controls. Light gray and dark gray bars correspond to LC-MS and DIMS acquisitions, respectively. The boxes are drawn from the 25th to 75th
percentiles in the intensity distribution. The median, or 50th percentile, is drawn as a black horizontal line inside the box. The whiskers extend from the

































































View Onlinepretreatment and different matrix complexities. The pretreat-
ment of LC-MS data, including peak alignment and data
reduction, is still problematic and increases the uncertainty of the
quantitative result. In DIMS, ion suppression may hinder its
ability to reflect true concentration differences.
As shown in Fig. 7, an obvious decline of LPC (16 : 0) and
LPC (18 : 0) and an increase of phenylacetylglycine and
Ganglioside GM3 were observed by both methods in kidney
cancer patients compared to controls. LPC is formed by the
hydrolysis of phosphatidylcholine by the enzyme phospholipase
A2 or lecithin-cholesterol acyltransferase (LCAT). It regulates
many biological process, including cell proliferation, tumor cell
invasiveness, and inflammation.33 A distinct decline of LPC was
observed in our study, which is in agreement with the earlier
study on kidney cancer by 31P-NMR spectroscopy.41 Similar
trends were also found in other malignant diseases, such as
leukemia, malignant lymphomas, gastrointestinal and liver
cancer.38,42 Serum LPC concentrations might be developed as
a general indicator for malignant disease.
The obvious increase of phenylacetylglycine revealed a disor-
dered fatty acid metabolism in kidney cancer patients. Phenyl-
acetylglycine is an acyl glycine, which is normally a minor
metabolite of fatty acids. In certain cases, the measurement of acyl
glycines in body fluids can be used to diagnose disorders associ-
ated with mitochondrial fatty acid beta-oxidation.43,44 Similar
changes were reported in a recent study on chemically-induced
precancerous colorectal lesions.45 Phenylacetylglycine is also
a putative biomarker of phospholipidosis.46 Urinary phenyl-
acetylglycine concentration was reported to increase in animals
exhibiting abnormal phospholipid accumulation in many tissues.47
Gangliosides (sialic acid-containing glycosphingolipids) are
synthesized from ceramide and have attracted considerable
interest for more than 20 years as potential targets for cancer
diagnosis because of their relevance in tumor growth and
metastasis.48,49 The ganglioside GM3 is one of the main
components of the total gangliosides in many cell types.50 It
inhibits proliferation of epidermoid carcinoma cells and neuro-
blastoma cells by suppressing activity of the relevant cell growth
factor receptor.51,52 Over-expression of ganglioside GM3 has
been found in several kinds of tumors,49,53 which is in agreement
with our kidney cancer study.This journal is ª The Royal Society of Chemistry 2010The discovery of these biomarkers not only gives a better
understanding of the pathophysiological changes of kidney
cancer but also indicates possible chemotherapy for patients. The
quantification of these metabolites could be significant in further
studies as an aid in the prognostication of kidney cancer.Conclusion
The performance of LC-MS and DIMS on serum metabonomic
study was compared using the same mass spectrometer. Patients
with kidney cancer and healthy volunteers were used as real
models. DIMS had comparable classification and prediction
capability to LC-MS. With regard to biomarker discovery, 23
variables were found as potential markers by DIMS, while 48
variables were obtained by LC-MS. Most biomarkers obtained
by DIMS were also observed by LC-MS, and the trends of
alteration of the corresponding biomarkers were similar.
Considering that a much higher throughput can be obtained
without a chromatographic step, DIMS could be developed as
a fast prognostic or diagnostic method for kidney cancer. The
LC-MS method is necessary when comprehensive screening of
biomarkers is required.Acknowledgements
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